Next Article in Journal
Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation
Previous Article in Journal
QSAR and Molecular Docking Studies of Oxadiazole-Ligated Pyrrole Derivatives as Enoyl-ACP (CoA) Reductase Inhibitors
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2015). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessArticle
Sci. Pharm. 2014, 82(1), 87-98; https://doi.org/10.3797/scipharm.1308-15 (registering DOI)

Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound

1
Lotus Labs Pvt. Ltd, Bangalore, India
2
Birla Institute of Technology, Ranchi, India
3
Lotus Clinical Research Academy, Bangalore, India
4
Institute of Chemical Technology, Mumbai, India
*
Author to whom correspondence should be addressed.
Received: 31 August 2013 / Accepted: 21 October 2013 / Published: 21 October 2013
PDF [1261 KB, uploaded 27 September 2016]

Abstract

Cyclohex-3-enyl(5-phenyl-4H-1,2,4-triazol-3-yl)methanol (MSDRT 12) is a novel triazole-based antitubercular compound with two chiral centers. To evaluate the enantiospecific antitubercular activity, the four stereoisomers were isolated using preparative chiral chromatography and the individual stereoisomers were evaluated using the resazurin microtiter assay method (REMA) and a microbroth dilution technique against the Mycobacterium tuberculosis H37Rv strain. Isomer III of MSDRT 12 was found to be the most potent with a minimum inhibitory concentration (MIC) of 0.78 μg/mL, Isomer II had a MIC of 12.5 μg/mL, and isomers I and IV showed no activity. The diastereomeric mixture of MSDRT 12 showed a MIC of 3.125 μg/mL and isoniazid, used as the standard drug, showed a MIC of 0.4 μg/mL. This confirms the necessity of screening individual enantiomers for their pharmacological activity early in the discovery phase to identify the most potent isomer for further development efforts.
Keywords: Chiral Separation; Preparative Chiral Chromatography; Triazoles; Antitubercular Compounds; REMA testing Chiral Separation; Preparative Chiral Chromatography; Triazoles; Antitubercular Compounds; REMA testing
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

SHEKAR, R.; SINHA, B.N.; MUKHOPADHYA, A.; DEGANI, M.S. Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound. Sci. Pharm. 2014, 82, 87-98.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top